144 related articles for article (PubMed ID: 33111088)
1. Protocol for Single-Cell Analysis of Tumor-Infiltrating B Cells Isolated from Human Breast Cancer Tissue Before and After Neo-adjuvant Chemotherapy.
Lu Y; Liao JY; Su S
STAR Protoc; 2020 Jun; 1(1):100040. PubMed ID: 33111088
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer.
Yamaguchi R; Tanaka M; Yano A; Tse GM; Yamaguchi M; Koura K; Kanomata N; Kawaguchi A; Akiba J; Naito Y; Ohshima K; Yano H
Hum Pathol; 2012 Oct; 43(10):1688-94. PubMed ID: 22516244
[TBL] [Abstract][Full Text] [Related]
3. Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.
Lee KH; Kim EY; Park YL; Do SI; Chae SW; Park CH
Tumour Biol; 2017 Jun; 39(6):1010428317710575. PubMed ID: 28621227
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy alters peripheral and tumour-infiltrating immune cells in breast cancer revealed by single-cell RNA sequencing.
Zhou H; Li G; Yin J; Wang T; Hu H; Li T; Zhou Q; Hu J; Wang L; Dong S; Wei C; Zhang C; Lu Y; Zhou W; Huang C; Yang H; Zhou D; Wang L; Wu K
Clin Transl Med; 2021 Dec; 11(12):e621. PubMed ID: 34919339
[No Abstract] [Full Text] [Related]
5. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
Pelekanou V; Barlow WE; Nahleh ZA; Wasserman B; Lo YC; von Wahlde MK; Hayes D; Hortobagyi GN; Gralow J; Tripathy D; Porter P; Szekely B; Hatzis C; Rimm DL; Pusztai L
Mol Cancer Ther; 2018 Jun; 17(6):1324-1331. PubMed ID: 29588392
[TBL] [Abstract][Full Text] [Related]
7. The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
Eustace AJ; Madden SF; Fay J; Collins DM; Kay EW; Sheehan KM; Furney S; Moran B; Fagan A; Morris PG; Teiserskiene A; Hill AD; Grogan L; Walshe JM; Breathnach O; Power C; Duke D; Egan K; Gallagher WM; O'Donovan N; Crown J; Toomey S; Hennessy BT
Breast Cancer Res Treat; 2021 Jun; 187(3):635-645. PubMed ID: 33983492
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy.
Melichar B; Študentova H; Kalábová H; Vitásková D; Čermáková P; Hornychová H; Ryška A
Anticancer Res; 2014 Mar; 34(3):1115-25. PubMed ID: 24596349
[TBL] [Abstract][Full Text] [Related]
9. Relevance of tumor-infiltrating lymphocytes in breast cancer.
Dushyanthen S; Beavis PA; Savas P; Teo ZL; Zhou C; Mansour M; Darcy PK; Loi S
BMC Med; 2015 Aug; 13():202. PubMed ID: 26300242
[TBL] [Abstract][Full Text] [Related]
10. Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1
Liang H; Li H; Xie Z; Jin T; Chen Y; Lv Z; Tan X; Li J; Han G; He W; Qiu N; Jiang M; Zhou J; Xia H; Zhan Y; Cui L; Guo W; Huang J; Zhang X; Wu YL
Thorac Cancer; 2020 Oct; 11(10):2941-2954. PubMed ID: 32894006
[TBL] [Abstract][Full Text] [Related]
11. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis.
Yokotani T; Ikeda N; Hirao T; Tanaka Y; Morita K; Fujii T; Ohbayashi C; Nakamura T; Kobayashi T; Sho M
Surg Today; 2021 Apr; 51(4):595-604. PubMed ID: 33052489
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
West NR; Milne K; Truong PT; Macpherson N; Nelson BH; Watson PH
Breast Cancer Res; 2011; 13(6):R126. PubMed ID: 22151962
[TBL] [Abstract][Full Text] [Related]
14. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Dieci MV; Frassoldati A; Generali D; Bisagni G; Piacentini F; Cavanna L; Cagossi K; Puglisi F; Michelotti A; Berardi R; Banna G; Goubar A; Ficarra G; Griguolo G; Conte P; Guarneri V
Breast Cancer Res Treat; 2017 Jun; 163(2):295-302. PubMed ID: 28289852
[TBL] [Abstract][Full Text] [Related]
16. Quantification of residual risk of relapse in breast cancer patients optimally treated.
Dieci MV; Arnedos M; Delaloge S; Andre F
Breast; 2013 Aug; 22 Suppl 2():S92-5. PubMed ID: 24074801
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating Lymphocyte Score Based on FDG PET/CT for Predicting the Effect of Neoadjuvant Chemotherapy in Breast Cancer.
Sasada S; Kimura Y; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
Anticancer Res; 2020 Jun; 40(6):3395-3400. PubMed ID: 32487636
[TBL] [Abstract][Full Text] [Related]
18. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
19. Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
König L; Mairinger FD; Hoffmann O; Bittner AK; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A
BMC Cancer; 2019 Feb; 19(1):120. PubMed ID: 30717704
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
Inoue H; Horii R; Ito Y; Iwase T; Ohno S; Akiyama F
Breast Cancer; 2018 May; 25(3):268-274. PubMed ID: 29185202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
